Company Information
- CEO
- Giacomo Di Nepi
- Investor Relations
- Kalina Scott
Polyphor is a clinical stage, held Swiss biopharmaceutical company which has discovered and is developing the OMPTA (Outer Membrane Protein Targeting Antibiotics). The OMPTA are potentially the first new class of antibiotics against Gram-negative bacteria to have reached phase III stage in the last 50 years. The companys lead product, murepavadin, (POL7080) is in Phase III development against Pseudomonas aeruginosa recognized as a critical priority 1 pathogen by WHO. Polyphor is also developing an immuno-oncology candidate, balixafortide (POL6326), which has achieved clinical proof of concept in a Phase Ib/proof of concept study in combination with eribulin in patients with advanced breast cancer, and a pipeline of further preclinical antibiotics based on its OMPTA platform. Polyphor is based in Allschwil near Basel.
Trading Information
- Sector
- Health Care - 4500
- Regulatory Standard
- International Reporting Standard
- Security Number
- 10621379
- ISIN
- CH0106213793
- Symbol
- POLN
- Index member
- SPI/SPIEX/SXSLI + SXI Bio+Medtech + SXI Life Sciences
Intermediaries
- Listing Agent
- UBS AG
- Lead Bank
- UBS & Deutsche Bank
- Auditor
- Ernst & Young
Information on the Issue
| Security Details | |
|---|---|
| First Listing | 15.05.2018 |
| Class of Share | Action nominative |
| Nominal Value | 2.00 CHF |
| Total Shares outstanding (post issue; incl. Greenshore - if any) | 11040753 |
| Allocation Details | |
|---|---|
| Primary Shares | 4078950 |
| Secondary Shares | n/a |
| Primary Greenshoe | 263160 |
| Secondary Greenshoe | n/a |
| Greenshoe Details | |
|---|---|
| Executed | no |
| Ex-date | 30.11.2002 |
| Executed number of shares | n/a |
| First Trading Day Details | |
|---|---|
| First Trading | 15.05.2018 |
| Price Range | 30.00 - 40.00 CHF |
| Issue Price | 38.00 CHF |
| First Open | 40.00 CHF |
| First Close | 38.20 CHF |
| Transaction size in Mio. (incl. executed Greenshoe) | 155 CHF |
| Market Capitalisation in Mio. (based on first closing price) | 422 CHF |
Financial Statement
| Number of Employees | 101 |
| Net Revenues in Mio. | 4.3 CHF |
| Net Gain in Mio. | n/a |